Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy

Bayer's experimental non-hormonal drug, elinzanetant, demonstrated significant efficacy in late-stage trials, with over 70% of patients reporting at least a 50% reduction in moderate-to-severe hot flashes caused by breast cancer hormone therapy, addressing a critical unmet need that often leads to treatment non-adherence as it nears FDA and EMA approval. Concurrently, new research suggests existing FDA-approved JAK inhibitors, like Pfizer's Xeljanz, can mitigate or reverse type 1 diabetes induced by cancer immunotherapies, potentially expanding their market use and improving survivorship for patients on blockbuster checkpoint inhibitors.

Analysis

The report highlights two significant, positive developments in oncology and supportive care. First, Bayer's experimental drug, elinzanetant, has shown considerable efficacy in a late-stage trial for treating moderate-to-severe hot flashes in breast cancer patients on hormone-suppressing therapy. With over 70% of participants on the drug reporting at least a 50% reduction in symptoms compared to 36% in the placebo group, the drug addresses a critical unmet need that contributes to high rates of non-adherence to life-saving cancer treatments. The pending FDA and European Medicines Agency approval positions elinzanetant as a potentially new standard of care, leveraging a non-hormonal mechanism recently validated by the FDA's approval of Astellas' Vezoah for general menopause. Secondly, early-stage laboratory research indicates that existing FDA-approved JAK inhibitors from Pfizer, AbbVie, and Eli Lilly may prevent or reverse type 1 diabetes induced by checkpoint inhibitors like Merck's Keytruda and Bristol Myers Squibb's Opdivo. While this side effect affects only 1-2% of patients receiving these immunotherapies, the finding presents a potential label-expansion opportunity for the JAK inhibitor class and could improve the long-term safety profile and patient retention for these blockbuster cancer therapies.

Key Decisions for Investors

• Investors should monitor the upcoming FDA and EMA approval decisions for Bayer's elinzanetant, as a positive outcome could establish a new standard of care and create a significant market opportunity in oncology supportive care.
• For holders of Pfizer, AbbVie, and Eli Lilly, the research on JAK inhibitors represents a potential long-term, incremental value driver through label expansion, though it should be recognized as early-stage and not a near-term catalyst.
• The potential to mitigate a serious side effect of checkpoint inhibitors is a net positive for Merck and Bristol Myers Squibb, as it could de-risk their key immunotherapy franchises by improving patient safety and adherence, thereby supporting the long-term revenue stability of these blockbuster drugs.